title: The activation of platelet function, coagulation, and fibrinolysis during radiofrequency catheter ablation in heparinized patients.
abstract: BACKGROUND
  Catheter ablation may be complicated by clinical thromboembolism in about 1% of patients.
  
  
  RESULTS
  We studied the activation of coagulation (prothrombin fragment 1+2 [PF1+2]), platelets (beta-thromboglobulin [beta-TG])) and fibrinolysis (plasmin-antiplasmin complexes [PAP] and D-dimer) during radiofrequency (RF) ablation in 13 patients. They received heparin 100 U/kg intravenously after the initial electrophysiologic study, prior to the delivery of RF current; thereafter 1,000 U/hour throughout the procedure. PF1+2 increased fourfold (P < 0.001) during the diagnostic study, but gradually declined to upper reference value during heparin administration. There was a strong correlation between procedure duration prior to heparin bolus (range 39 to 173 min); and (a) the maximal rise of PF1+2 (r = 0.83, P < 0.001) and (b) the increase of PF1+2 from baseline to end of the procedure (r = 0.74, P = 0.004). There was no correlation between postheparin changes of PF1+2 and (a) postheparin procedure duration (range 40 to 317 min), (b) number of RF pulses (range 1 to 16), or (c) RF current duration (range 46 to 687 sec). Plasma beta-TG concentration showed similar trends. Fibrinolytic activity increased moderately from baseline until heparin administration; then remained around the upper reference values. PAP at the end of procedure and D-dimer at the time of heparin administration both correlated with preheparin procedure duration (r = 0.70, P = 0.007 and r = 0.69, P = 0.01, respectively). All parameters were normal the next morning.
  
  
  CONCLUSIONS
  Procedure duration prior to heparin administration, and not the delivery of RF current per se, determines activation of hemostasis and fibrinolysis during RF ablation.
authors.affiliation: Department of Cardiology, Rikshospitalet, University of Oslo, Norway. o.g.anfinsen@klinmed.uio.no
authors.forename: O G
authors.initials: OG
authors.lastname: Anfinsen
authors.forename: K
authors.initials: K
authors.lastname: Gjesdal
authors.forename: F
authors.initials: F
authors.lastname: Brosstad
authors.forename: O M
authors.initials: OM
authors.lastname: Orning
authors.forename: H
authors.initials: H
authors.lastname: Aass
authors.forename: E
authors.initials: E
authors.lastname: Kongsgaard
authors.forename: J P
authors.initials: JP
authors.lastname: Amlie
mesh_terms: D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage*; D001777:Blood Coagulation / Q000502:physiology*; D001792:Blood Platelets / Q000502:physiology; D017115:Catheter Ablation; D004562:Electrocardiography; D005260:Female; D005342:Fibrinolysis / Q000502:physiology*; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D016343:Monitoring, Intraoperative; D015539:Platelet Activation / Q000502:physiology*; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000097:blood / Q000150:complications / Q000601:surgery*; D013923:Thromboembolism / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D006493:Heparin